Edition:
United States

Delcath Systems Inc (DCTH.OQ)

DCTH.OQ on NASDAQ Stock Exchange Capital Market

0.16USD
24 Feb 2017
Change (% chg)

$-0.01 (-5.01%)
Prev Close
$0.17
Open
$0.17
Day's High
$0.17
Day's Low
$0.16
Volume
655,185
Avg. Vol
511,960
52-wk High
$6.72
52-wk Low
$0.13

DCTH.OQ

Chart for DCTH.OQ

About

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $0.35
Shares Outstanding(Mil.): 2.20
Dividend: --
Yield (%): --

Financials

  DCTH.OQ Industry Sector
P/E (TTM): -- 34.59 29.63
EPS (TTM): -10.07 -- --
ROI: -112.21 12.50 12.96
ROE: -161.99 14.56 14.11

BRIEF-Delcath Systems enters agreement with holders of more than 55 pct of aggregate principal amount of senior secured convertible notes Due Dec 29, 2017

* Delcath Systems - co, holders of more than 55 pct of aggregate principal amount of senior secured convertible notes due Dec 29, 2017 entered agreement

Feb 23 2017

BRIEF-Barbra C. Keck became CFO of Delcath Systems effective Feb. 21- SEC filing

* Effective February 21, 2017, Barbra C. Keck became chief financial officer of company - SEC filing Source text for Eikon: Further company coverage: ;))

Feb 22 2017

BRIEF-Empery Asset Management LP dissolves passive stake in Delcath Systems

* Empery Asset Management LP dissolves passive stake in Delcath Systems Inc as of Dec 30, 2016 - SEC filing

Jan 31 2017

BRIEF-Delcath announces patient treatment in intrahepatic Cholangiocarcinoma study

* Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing

Jan 12 2017

BRIEF-Delcath Q3 loss $0.66/shr

* Believes it has sufficient capital to fund its operating activities through end of 2017

Nov 11 2016

BRIEF-Delcath Systems issues letter to stockholders

* Assuming conditions are satisfied, expect anticipated qtrly releases throughout 2017 will fund clinical development plan through 2017-end Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Delcath Systems announces new clinical sites for FOCUS Phase 3 trial for ocular melanoma liver metastases

* Delcath Systems - 5 new clinical trial sites in U.S. have been activated in global FOCUS Phase 3 clinical trial for ocular melanoma liver metastases

Oct 11 2016

BRIEF-Delcath prices underwritten public offering at $3.00 per share

* Delcath prices underwritten public offering of common stock and warrants

Sep 30 2016

BRIEF-Delcath announces proposed public offering of common stock and warrants

* Delcath announces proposed public offering of common stock and warrants

Sep 29 2016

More From Around the Web

Earnings vs. Estimates